Analysis – Ozempic on Wall Street’s list for 2027 Medicare drug negotiations
By Michael Erman NEW YORK (Reuters) – Now that the U.S. government has negotiated prices for some Medicare drugs that will take effect in 2026, Wall Street analysts are betting that a list will appear in 2027 that will include Novo Nordisk’s blockbuster Ozempic for diabetes and will have only a limited impact on major […]
